Table 2 This table summarizes the components constituting the GDMT score
From: Digital consults in heart failure care: a randomized controlled trial
Baseline | 12-week follow-up | Increase | P value | |
|---|---|---|---|---|
ACE/ARB/ARNI (mean, s.d.) | ||||
Treatment | 0.53 (±0.37) | 0.70 (±0.36) | 0.17 (±0.32) | |
Usual care | 0.49 (±0.34) | 0.59 (±0.35) | 0.10 (±0.26) | 0.164 |
Switch to ARNI (n, %) | ||||
Treatment | 35 (44.9%) | 56 (71.8%) | 22 (28.2%) | |
Usual care | 40 (55.6%) | 50 (69.4%) | 10 (13.9%) | 0.053 |
β-Blocker (mean, s.d.) | ||||
Treatment | 0.62 (±0.40) | 0.80 (±0.34) | 0.17 (±0.33) | |
Usual care | 0.54 (±0.42) | 0.62 (±0.41) | 0.07 (±0.22) | 0.028 |
MRA (mean, s.d.) | ||||
Treatment | 0.40 (±0.38) | 0.67 (±0.39) | 0.27 (±0.39) | |
Usual care | 0.37 (±0.35) | 0.47 (±0.39) | 0.10 (±0.25) | 0.002 |
SGLT2i (n, %) | ||||
Treatment | 43 (55.1%) | 68 (87.2%) | 25 (32.1%) | |
Usual care | 49 (68.1%) | 56 (77.8%) | 7 (9.7%) | <0.001 |
Iron screening/supplementation (n, %) | ||||
Treatment | 14 (17.9%) | 45 (57.7%) | 31 (39.7%) | |
Usual care | 12 (16.7%) | 17 (23.6%) | 5 (6.9%) | <0.001 |
Patients with at least one uptitration before reaching OMT (n, %) | ||||
Treatment | 18 (81.8%) | |||
Usual care | 3 (60.0%) | |||
